Introduction
============

Cancer metastasis is the process of cancer cells disseminating from the primary tumor to a distal site through lymphatic tissue and blood vessels. Cancer metastasis is responsible for approximately 90% of cancer deaths, indicating that it is the primary cause of morbidity and mortality ([@b1-ol-0-0-11375]). Even though most solid tumors are now manageable or curable by advances in early cancer detection and treatment, cancers spreading beyond the initial primary site are usually highly incurable ([@b2-ol-0-0-11375]). Lack of understanding of the mechanism underlying the metastatic process has meant that the predominant cancer treatments focus on inhibition of cancer growth with little emphasis on metastasis, meaning that the overall survival of metastatic cancer patients has not been improved significantly.

Transforming growth factor-β (TGFβ) is one of the master factors of metastasis in that it induces the epithelial-mesenchymal transition (EMT), which is associated with cancer. EMT is the reversible orchestrated transcriptional program in which well-organized, tightly connected epithelial cells transdifferentiate into disorganized and motile mesenchymal cells. TGF-β signaling mediated by SMAD or non-SMAD pathways plays a fundamental role in activating the transcriptional network to induce the expression of mesenchymal components and to suppress the expression of epithelial genes ([@b3-ol-0-0-11375],[@b4-ol-0-0-11375]). As a result, epithelial cancer cells undergo dramatic remodeling of the cytoskeleton along with dissolution of tight junctions to acquire mesenchymal features that exhibit a significantly enhanced metastatic dissemination potential into distal organs. This event is induced by the activity of master regulators of EMT, which include SNAIL, SLUG, ZEB1/delta EF1 and ZEB2/SIP1 ([@b5-ol-0-0-11375]--[@b8-ol-0-0-11375]).

ELK3 is an ETS domain-containing protein capable of forming a ternary complex with DNA and serum response factor ([@b9-ol-0-0-11375]). ELK3 is reported to be involved in the migration and invasion of various cancer cells including aggressive basal-like breast cancer cells and liver cancer stem cells ([@b10-ol-0-0-11375],[@b11-ol-0-0-11375]). Previously, we reported that ELK3 suppression impairs the ability of TGFβ signaling to activate the expression of mesenchymal markers such as Vimentin, Slug and SNAIL in the triple negative breast cancer cells, which suggests that ELK3 is implicated in the TGFβ signaling pathway to regulate the metastatic process of aggressive cancer cells ([@b12-ol-0-0-11375],[@b13-ol-0-0-11375]).

In the present study, to extend our understanding of the molecular implication of ELK3 to the TGFβ signaling pathway in cancer cells, we analyzed the regulatory mechanism of TGFβ signaling on ELK3 expression. We found that TGFβ stimulates the transcriptional expression of ELK3 in the representative triple negative breast cancer cell line, MDA-MB231. Furthermore, based on the biochemical and molecular biology study, we demonstrated that TGFβ-mediated phosphorylation of SMAD3 functions as a transcriptional activator of ELK3. Taken together, our data reveal that ELK3 is a direct downstream target of TGFβ-SMAD3 signaling pathway in MDA-MB231 cells.

Materials and methods
=====================

### Plasmids, siRNA and primers

Information on the plasmids and siRNAs is summarized in the supplementary [Tables SI](#SD1-ol-0-0-11375){ref-type="supplementary-material"} and [SII](#SD1-ol-0-0-11375){ref-type="supplementary-material"}.

### Cell culture and transfection

The triple negative breast cancer cell line MDA-MB231 and the human breast adenocarcinoma cell line MCF7 and the human embryonic kidney 293T cells were purchased from American Type Culture Collection (Manassas, VA, USA). These cells were maintained in DMEM (Gibco BRL Life Technologies, Rockville, MD, USA) containing 10% (v/v) heat-inactivated fetal bovine serum (Gibco BRL). 293T cells were used for the luciferase assay with the pGL3-ELK3 plasmid. Transient transfection of plasmid DNA or siRNA was performed with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer\'s protocols.

### RNA extraction and reverse transcription-quantitative (RT-q)PCR

Total RNA was extracted by manual methods using TRIZol (Invitrogen), and 1 µg of cDNA was synthesized using the LeGene Express 1st Strand cDNA Synthesis System (LeGene Biosciences Inc., San Diego, CA, USA) according to the manufacturer\'s instructions. RT-qPCR was performed using synthetic cDNAs and TOPreal™ qPCR 2X PreMIX (Enzynomics, Daejeon, Korea). The expression of the target genes was normalized to that of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The PCR primers are listed in [Table SIII](#SD1-ol-0-0-11375){ref-type="supplementary-material"}.

### Immunoblot analysis

Cells were lysed with RIPA buffer (Cell Signaling Technology, Beverly, MA, USA) and total cell lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA, USA). The membranes were blotted with the indicated primary antibodies at 4°C overnight. After washing with TBST, the membranes were incubated for 1 h at room temperature with secondary antibodies. Immunoreactivity was detected with an ECL kit (Thermo Scientific, Rochester, NY, USA). The antibodies used in this study are summarized in [Table SIV](#SD1-ol-0-0-11375){ref-type="supplementary-material"}.

### Luciferase assay

The 293T cells were transfected with the indicated plasmids using Lipofectamine 2000 (Invitrogen) according to the manufacturer\'s protocols. Cells were harvested 48 h after transfection, and luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer\'s protocols. The values of firefly luciferase were normalized to the respective values of *Renilla* luciferase.

### Chromatin immunoprecipitation

In brief, 37% formaldehyde was added to the cell culture medium to a final concentration of 1% and incubated for 15 min at RT. Glycine was added to a final concentration of 125 mM for 5 min at RT, and the cells were washed three times with cold PBS. The cells were lysed in 400 µl of 1X cell lysis buffer (Cell Signaling) containing protease/phosphatase inhibitor cocktail (Pierce Biotechnology). After eight rounds of sonication, the lysates were cleared by centrifugation at 13,000 rpm for 15 min at 4°C. The supernatants were mixed with 40 µl of Dynabead protein G and 2 µg of primary antibodies for 2 h at RT or overnight at 4°C. The complexes were washed sequentially with 1X RIPA buffer, 1X RIPA buffer (500 mM NaCl), LiCl buffer and TE buffer twice for 10 min each. Then, 3 µl of 10% SDS and 5 µl of 20 mg/ml proteinase K were added to separate the DNA-protein complex. The DNA was purified by the phenol/chloroform extraction method, and then it was used in PCR with primers targeting the ELK3 promoter.

### Statistical analysis

Samples were analyzed with Student\'s t-test or ANOVA with Duncan\'s multiple range procedure for multiple comparisons. All statistical analyses were performed using GraphPad Prism 5 (GraphPad Prism, USA) or the SigmaPlot 11.2 program (Systat Software, USA). All statistical analyses were performed using GraphPad Prism 5 (GraphPad Prism, USA). The error bars represent the standard errors from three independent experiments, which were each performed using triplicate samples. P-values less than 0.05 were considered statistically significant.

Results
=======

### TGFβ induces accumulation of ELK3 in the nucleus of MDA-MB231 cells, but not in MCF7 cells

Cancer cells treated with TGFβ undergo the EMT process by developing a fibroblast-like morphological appearance and changing epithelial and mesenchymal phenotype marker expression. Unlike MDA-MB231 cells, TGFβ-treated MCF7 cells that display morphological changes of EMT do not show suppression of E-cadherin, a typical epithelial phenotype marker ([@b14-ol-0-0-11375]). Recently, we reported that *ELK3* is highly expressed in TNBC-like MDA-MB231 cells, where it functions as a transcriptional repressor of *E-cadherin* by collaborating with ZEB1 ([@b15-ol-0-0-11375]). Therefore, we hypothesized that ELK3 is the missing link that explains the different molecular responses of MDA-MB231 and MCF7 cells when they are treated with TGFβ. We first compared the expression of *ELK3* between MDA-MB231 and MCF7 cells following TGFβ treatment. As expected, TGFβ stimulated *ELK3* expression in MDA-MB231 cells but not in MCF7 cells ([Fig. 1A](#f1-ol-0-0-11375){ref-type="fig"}). Consistently, ELK3 protein was also accumulate in the TGFβ-treated MDA-MB231 cells ([Fig. 1B](#f1-ol-0-0-11375){ref-type="fig"}). Immunocytochemical analysis and subcellular fractionation assays of the cytosol and nucleus confirmed that ELK3 accumulates in the TGFβ-treated MDA-MB231 cells ([Fig. 1C and D](#f1-ol-0-0-11375){ref-type="fig"}). Overall, these data indicate that TGFβ induces transcriptional activation of *ELK3* in MDA-MB231 cells but not in MCF7 cells.

### TGFβ activates ELK3 expression via SMAD3

To understand the underlying mechanism of ELK3 activation by TGFβ treatment, we examined the effect of SB431542, an inhibitor of TGFβ type I receptor, on the TGFβ-mediated *ELK3* expression. As shown in [Fig. 2A](#f2-ol-0-0-11375){ref-type="fig"}, pretreatment with SB431542 inhibited mRNA and protein accumulation of ELK3 in the TGFβ-treated MDA-MB231 cells. Consistent with the result of chemical inhibition, transfection of siRNA targeting TGFβ type I receptor abolished the effect of TGFβ on the transcriptional activation of *ELK3* ([Fig. 2B](#f2-ol-0-0-11375){ref-type="fig"}). We next questioned whether *ELK3* expression is regulated by SMAD2 or SMAD3. Like *SNAIL*, which is a downstream target of SMAD3, transfection of an siRNA targeting *SMAD3 (siSMAD3)* hindered the TGFβ-mediated expression of *ELK3*, whereas an siRNA targeting *SMAD2 (siSMAD2)* did not interfere with the TGFβ effect on *ELK3 or SNAIL* expression ([Fig. 2C](#f2-ol-0-0-11375){ref-type="fig"}). The increase in expression of *ELK3* over time in TGFβ-treated MDA-MB231 cells was similar between the control and *siSMAD2* transfected MDA-MB231 cells, whereas *siSMAD3* transfection abolished the effect of TGFβ on *ELK3* expression ([Fig. 2D](#f2-ol-0-0-11375){ref-type="fig"}). Taken together, these results suggest that TGFβ-mediated transcriptional activation of ELK3 is mediated by SMAD3.

### SMAD3 binds to the ELK3 promoter to activate the transcription of ELK3 upon TGFβ treatment

To analyze whether SMAD3 functions as a direct transcriptional activator of *ELK3*, we examined the sequences of mouse and human *ELK3* promoters from −2,000 bp to the first exon region. We found that two SMAD3 binding sites (SBE) are conserved at the first exon of the *ELK3* promoter in the human and mouse genomes. Therefore, we constructed a luciferase reporter construct containing the promoter region of *ELK3* from −92 bp to +345 bp ([Fig. 3A](#f3-ol-0-0-11375){ref-type="fig"}). To assess whether SMAD3 functions as a direct transcriptional activator of the *ELK3* promoter, the reporter plasmid containing the *ELK3* promoter was cotransfected into 293T cells with plasmids encoding a constitutively active form of the TGFβ type I receptor (CA-ALK5) or SMAD3. As shown in [Fig. 3B](#f3-ol-0-0-11375){ref-type="fig"}, the ELK3 reporter plasmid is activated only when ectopically expressed SMAD3 is phosphorylated by cotransfection of the CA-ALK5-expressing plasmid in 293T cells. To confirm that SMAD3 directly binds to the SBE of the *ELK3* promoter, we performed chromatin immunoprecipitation (ChIP) analysis with anti-SMAD3 antibody against genomic DNA of MDA-MB231 with or without TGFβ treatment. Since ID1, an inhibitor of differentiation, is a direct downstream target of SMAD3 ([@b16-ol-0-0-11375]), it was used as a positive control in the ChIP analysis. Like ID1, the SBE region of the *ELK3* promoter was significantly enriched by immunoprecipitation with the anti-SMAD3 antibody upon TGFβ stimulation ([Fig. 3C](#f3-ol-0-0-11375){ref-type="fig"}). Taken together, we concluded that SMAD3 activates transcription of *ELK3* by directly binding to the SBE region of the *ELK3* promoter following TGFβ treatment.

Discussion
==========

During cancer development and progression in malignancy, the TGFβ signaling pathway acts as a tumor promotor by driving EMT, which induces tumor cell migration, invasion and ultimately metastasis to distant organs. ELK3 is constitutively activated in basal triple negative breast cancer cells (TNBCs) and functions as a master regulator of cancer metastasis ([@b10-ol-0-0-11375],[@b12-ol-0-0-11375]). Previously, we suggested that the TGFβ signaling pathway is interconnected with ELK3 activity, based on the fact that ELK3 knockdown in TNBCs induces collapse of TGFβ signaling ([@b12-ol-0-0-11375]). In this study, we demonstrated that ELK3 is transcriptionally activated by TGFβ treatment in TNBCs. Pharmacological and molecular analysis revealed that ELK3 is a direct downstream target of SMAD3. In addition, TGFβ induced migration was decreased in ELK3 knockdowned MDA-MB231 cells (data not shown).

There are numerous reports that the TGFβ signaling pathway is strictly regulated by a finely tuned system of negative and positive feedback loops. The expression of SMAD7, a representative inhibitory SMAD, is stimulated by TGFβ treatment and forms a complex with E3 ubiquitin ligase to degrade the TGFβ receptor, which results in the SMAD pathway inhibiting hyper activation of TGFβ signaling ([@b17-ol-0-0-11375]). During late stages of colorectal cancer, TGFβ activates miR-1269a expression targeting SMAD7, hence forming a positive feedback loop to promote metastasis ([@b18-ol-0-0-11375]). Since TGFβ signaling is impaired by ELK3 suppression and ELK3 expression is increased by TGFβ treatment, we suggest that TGFβ and ELK3 might form a positive autofeedback loop to promote the EMT process.

Numerous studies have shown that inhibition of EMT is considered an appropriate approach towards the prevention of metastasis of cancer. Since TGFβ functions as an inducer of EMT, blocking the TGFβ pathway is considered a promising strategy to inhibit EMT in cancer cells; cytotoxic drugs such as paclitaxel, which targets TGFβ receptor kinase, have been used to target the metastatic potential of breast cancer cells to colonize the lung ([@b19-ol-0-0-11375]). In line with this concept, ELK3 can be a prominent therapeutic target to prevent TGFβ-mediated metastasis of cancer cells. The potential value of ELK3 as a target of anticancer drug development is supported by the fact that TNBCs with reduced ELK3 activity completely lost their metastatic characteristics ([@b12-ol-0-0-11375]). It was shown that small molecule based inhibition of Ras/ERK-mediated ELK3 activity results in the inhibition of prostate cancer progression and metastasis in mice ([@b20-ol-0-0-11375]). It would be interesting to investigate whether simultaneous inhibition of the TGFβ pathway and ELK3 activity produces clinically effective therapeutic outcomes.

In summary, we suggest that ELK3 is a novel downstream target of the TGFβ-SMAD3 signaling pathway and that it performs a major role in directing the metastasis of cancer. TGF-β1 is preferentially expressed at the advancing tumor edges, where it promotes malignant progression and metastasis ([@b21-ol-0-0-11375]--[@b23-ol-0-0-11375]). To strengthen our findings, follow-up immunohistochemical studies are needed to demonstrate the accumulation of ELK3 at the site of excessive TGFβ expression on invasive tumors.
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![TGFβ induces accumulation of ELK3 in the nuclei of MDA-MB231 cells. (A) Effect of TGFβ on the expression of *ELK3* in MDA-MB231 and MCF7 cells was compared by RT-qPCR of cancer cells treated with TGFβ (5 ng/ml) for 24 h. \*\*P\<0.01. (B) The increase of ELK3 protein (right panel) upon TGFβ treatment (5 ng/ml) for the indicated time was analyzed by immunoblot assay. (C) Nuclear accumulation of ELK3 upon TGFβ treatment was examined in MDA-MB231 cells by immunocytochemical staining. Cells were treated with 5 ng/ml TGFβ for 12 h. (D) Nuclear accumulation of ELK3 was examined by immunoblot of nuclear and cytoplasmic fractions from MDA-MB231 cells treated with TGFβ for the indicated times. A loading control of the cytoplasmic fraction was estimated by GAPDH and a loading control of the nuclear fraction was estimated by Lamin B1 (left panel). For quantitative analysis, the mean density of each band was measured with Multi Gauge V3.0 software, and the band density of EL3 was divided by Lamin B1 to obtain the normalized band intensity (right panel). The error bars represent the standard errors from three independent experiments, which were each performed using triplicate samples. TGFβ, transforming growth factor-β; RT-qPCR, reverse transcription-quantitative PCR. \*\*P\<0.01 vs. 0 h; ^\#\#^P\<0.01 vs. 12 h.](ol-19-04-2749-g00){#f1-ol-0-0-11375}

![Effect of TGFβ on *ELK3* expression is mediated by SMAD3 but not by SMAD2. (A) Effect of chemical inhibition of the TGFβ receptor on the TGFβ-mediated activation of *ELK3*. Cells were pre-incubated with 10 µM SB431542 for 1 h and then treated with 10 ng/ml TGFβ for 24 h. Relative transcripts and protein levels of ELK3 and TGFβ receptor-I were analyzed by RT-qPCR (left panel) and immunoblot analysis (right panel), respectively. (B) Effect of molecular inhibition of TGFβ receptor-I on the TGFβ-mediated activation of *ELK3* expression. Non-specific or TGFβ receptor-I targeting siRNAs were transfected into MDA-MB231 cells for 24 h followed by treatment with 5 ng/ml of TGFβ for 24 h. Relative transcripts and protein levels of ELK3 and TGFβ receptor-I were analyzed by RT-qPCR (left panel) and immunoblot analysis (right panel), respectively. (C) Effect of molecular inhibition of *SMAD2* or *SMAD3* on the TGFβ-mediated activation of *ELK3* expression. Non-specific, *SMAD2* or *SMAD3* targeting siRNAs were transfected into MDA-MB231 cells for 24 h, which was followed by treatment with 5 ng/ml of TGFβ for 24 h. Knockdown effect of *SMAD2* and *SMAD3* was analyzed by immunoblot analysis (left panel). Relative transcripts and protein levels of ELK3 and SNAIL, which is a target of SMAD3, were analyzed by RT-qPCR (middle and right panel). (D) Effect of molecular inhibition of *SMAD2* or *SMAD3* on the TGFβ-treated, time-dependent activation of *ELK3* expression. Nonspecific, *SMAD2* or *SMAD3* targeting siRNAs were transfected into MDA-MB231 cells for 24 h, which was followed by treatment with 5 ng/ml of TGFβ for additional 24 h. The expression of *ELK3* was quantified by RT-qPCR. The error bars represent the standard errors from three independent experiments, which were each performed using triplicate samples. \*P\<0.05, \*\*P\<0.01. N.S, not significant; TGFβ, transforming growth factor-β; RT-qPCR, reverse transcription-quantitative PCR; si, small interfering; NS, non-specific.](ol-19-04-2749-g01){#f2-ol-0-0-11375}

![SMAD3 binds to the *ELK3* promoter to activate transcription upon TGFβ treatment. (A) Schematics of luciferase assay promoter construct of *ELK3* (−92 bp - +345 bp) (left panel). The right panel shows the DNA binding motif of SMAD3 in the *ELK3* promoter region of human (+225 bp - +257 bp) and mouse (+112 bp - +144 bp) genomes. (B) Effect of cotransfection of SMAD3 and constitutively active form of the TGFβ receptor-I (CA-ALK5) on the activity of the ELK3 promoter. Reporter plasmid containing the ELK3 promoter (pGL3-ELK3) was cotransfected into 293T cells with CA-ALK5 and SMAD3 expressing plasmids for 24 hrs. The expression of p-SMAD3, SMAD3 and CA-ALK5 was analyzed by immunoblot (left panel), and the activity of the *ELK3* promoter was analyzed by luciferase assay (right panel). (C) Chromatin from TGFβ-treated or nontreated MDA-MB231 cells were immunoprecipitated (ChIP) with antibodies against SMAD3 and IgG. The PCR results for the *ELK3* promoter region (+225 bp - +257 bp) are presented. SMAD3 binding to the ID1 promoter was used as a positive control of the ChIP experiment. The error bars represent the standard errors from three independent experiments, which were each performed using triplicate samples. \*\*P\<0.01. TGFβ, transforming growth factor-β; CA-ALK5, constitutively active form of TGFβ receptor-I; p, phosphorylated; ChIP, chromatin immunoprecipitation.](ol-19-04-2749-g02){#f3-ol-0-0-11375}
